Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
ALNY Quote, Financials, Valuation and Earnings
Last price:
$329.56
Seasonality move
:
-4.14%
Day range:
$302.55 - $318.44
52-week range:
$205.87 - $495.55
Dividend yield:
0%
P/E ratio:
139.29x
P/S ratio:
11.30x
P/B ratio:
52.84x
Volume:
1.5M
Avg. volume:
1.6M
1-year change:
18.69%
Market cap:
$41.7B
Revenue:
$3.7B
EPS (TTM):
$2.26
Analysts' Opinion
-
Consensus RatingAlnylam Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $459.40, Alnylam Pharmaceuticals, Inc. has an estimated upside of 48.74% from its current price of $314.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $310.00 representing -- downside risk from its current price of $314.40.
Fair Value
-
According to the consensus of 22 analysts, Alnylam Pharmaceuticals, Inc. has 48.74% upside to fair value with a price target of $459.40 per share.
ALNY vs. S&P 500
-
Over the past 5 trading days, Alnylam Pharmaceuticals, Inc. has overperformed the S&P 500 by 1.41% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Alnylam Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Alnylam Pharmaceuticals, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Alnylam Pharmaceuticals, Inc. reported revenues of $1.1B.
Earnings Growth
-
Alnylam Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Alnylam Pharmaceuticals, Inc. reported earnings per share of $1.37.
Enterprise value:
41.8B
EV / Invested capital:
0.00x
Price / LTM sales:
11.30x
EV / EBIT:
83.25x
EV / Revenue:
11.24x
PEG ratio (5yr expected):
-0.60x
EV / Free cash flow:
89.73x
Price / Operating cash flow:
90.18x
Enterprise value / EBITDA:
74.94x
Gross Profit (TTM):
$3B
Return On Assets:
6.83%
Net Income Margin (TTM):
8.45%
Return On Equity:
107.73%
Return On Invested Capital:
10.18%
Operating Margin:
12.01%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $1.8B | $2.2B | $3.7B | $593.2M | $1.1B | |
| Gross Profit | $1.5B | $1.9B | $3B | $490.3M | $829.3M | |
| Operating Income | -$282.2M | -$176.9M | $501.6M | -$105.2M | $131.7M | |
| EBITDA | -$228.1M | -$120.2M | $557.2M | -$91M | $145.2M | |
| Diluted EPS | -$3.56 | -$2.17 | $2.26 | -$0.65 | $1.37 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.8B | $2.7B | $3B | $3.3B | $4.1B | |
| Total Assets | $3.6B | $3.5B | $3.8B | $4.3B | $5B | |
| Current Liabilities | $695.7M | $767.9M | $967.8M | $1.2B | $1.5B | |
| Total Liabilities | $3.1B | $3.7B | $4.1B | $4.2B | $4.2B | |
| Total Equity | $588.2M | -$158.2M | -$220.6M | $67.1M | $789.2M | |
| Total Debt | $2.1B | $2.6B | $2.6B | $2.7B | $2.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $104.2M | -$8.3M | $524.1M | -$94.7M | $163.6M | |
| Cash From Investing | -$336.4M | -$116.8M | $436.3M | -$52.9M | -$37.2M | |
| Cash From Financing | $172.1M | $294.2M | -$305.2M | $31M | $45.3M | |
| Free Cash Flow | $41.9M | -$42.6M | $465.4M | -$103.8M | $140.3M | |
ALNY
Sector
Market Cap
$41.7B
$24M
Price % of 52-Week High
--
48.29%
Dividend Yield
0%
0%
Shareholder Yield
-0.57%
-1.6%
1-Year Price Total Return
18.69%
-22.92%
Beta (5-Year)
0.350
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$324.94
200-day SMA
Sell
Level
$386.50
Bollinger Bands (100)
Sell
Level
370.43 - 466.29
Chaikin Money Flow
Buy
Level
87M
20-day SMA
Sell
Level
$342.46
Relative Strength Index (RSI14)
Sell
Level
29.81
ADX Line
Sell
Level
34.3
Williams %R
Neutral
Level
-76.5948
50-day SMA
Sell
Level
$380.69
MACD (12, 26)
Sell
Level
-18.97
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
144.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.2737)
Sell
CA Score
(Annual)
Level (-1.5418)
Sell
Beneish M-Score
(Annual)
Level (-1.9118)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.0502)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, ALNY has received 14 Buy ratings 8 Hold ratings, and 0 Sell ratings. The ALNY average analyst price target in the past 3 months is $459.40.
-
Where Will Alnylam Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Alnylam Pharmaceuticals, Inc. share price will rise to $459.40 per share over the next 12 months.
-
What Do Analysts Say About Alnylam Pharmaceuticals, Inc.?
Analysts are divided on their view about Alnylam Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alnylam Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $310.00.
-
What Is Alnylam Pharmaceuticals, Inc.'s Price Target?
The price target for Alnylam Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $459.40 according to 22 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is ALNY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Alnylam Pharmaceuticals, Inc. is a Buy. 14 of 22 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALNY?
You can purchase shares of Alnylam Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alnylam Pharmaceuticals, Inc. shares.
-
What Is The Alnylam Pharmaceuticals, Inc. Share Price Today?
Alnylam Pharmaceuticals, Inc. was last trading at $329.56 per share. This represents the most recent stock quote for Alnylam Pharmaceuticals, Inc.. Yesterday, Alnylam Pharmaceuticals, Inc. closed at $314.40 per share.
-
How To Buy Alnylam Pharmaceuticals, Inc. Stock Online?
In order to purchase Alnylam Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ALNY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ALNY
Sector
P/E ratio
139.29x
23.25x
PEG ratio
-0.60x
-0.01x
P/B ratio
52.84x
1.73x
Price / LTM sales
11.30x
1.51x
Growth Metrics
ALNY
Sector
Revenue growth
84.95%
3.51%
Earnings growth
310.87%
11.14%
Revenue (5-year growth)
49.77%
6.27%
Earnings forecast
$1.50
-$0.19
Profitability
ALNY
Sector
Profitability FY 2025
$3B
$2.7M
Return on invested capital
10.18%
-33.58%
Return on assets
6.83%
-29.74%
Return on equity
107.73%
-38.98%
Earnings Date
Last Earnings Date
Feb
12
Next Earnings Date
Apr
30
Estimated Next Earnings Date
May
14
Balance Sheet
ALNY
Sector
Total cash
$2.9B
$24.9M
Short term investments
$1.7B
$23.9M
Total assets
$5B
$71.6M
Long term debt
$2.9B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 17
Cooper-Standard Holdings, Inc. [CPS] is down 1.46% over the past day.
Buy
58
TPH alert for Feb 17
Tri Pointe Homes, Inc. [TPH] is down 0.17% over the past day.
Sell
20
IRON alert for Feb 17
Disc Medicine, Inc. [IRON] is up 13.03% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
